explore -WSS

explore

author：comprehensive 2025-09-02 22:09:05 - browse：2

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

hotspot

focus

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Heat waves linked to early deliveries, preterm births in new study

Medical students need to learn the potent medicine of empathy

Guardant Health colon cancer test endorsed by FDA advisory panel

New research sheds light on how often breast cancer is overdiagnosed

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

leisure time

explore

focus

Psychedelics group wrestles with new pharma identity

Startling documents reveal new facets of Sacklers' opioid empire

Continuity nursing helped my family in our darkest PICU moments

U.S. death rates show how politics are affecting public health

Supreme Court strikes down use of affirmative action

Akili, maker of video game for ADHD, to be acquired for 34 million

Cancer drug shortages should be causing more outrage

Stigma and the return of syphilis

Virginia high school admissions case could be legal follow

Clinicians often fail to acknowledge the pain caused by long Covid

Wikipedia

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Childbirth

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

J&J reports mixed data on next

Medical students need to learn the potent medicine of empathy

Scientists successfully use ultrasound imaging to map brain activity

focus

hotspot

focus

hotspot